SCHEMBL4725548

SCHEMBL4725548

COc1cc(OCC2CC(O)CN2C(C)=O)c2c(Nc3ccc(F)c(Cl)c3)ncnc2c1

nearest known ligand 0.63

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
EGFR P00533 19/20 0.63
ERBB2 P04626 1/20 0.46
ERBB4 Q15303 1/20 0.46
EPHA2 P29317 1/20 0.45
KDR P35968 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522241 1.00 EGFR (0.63) EGFRERBB2ERBB4EPHA2KDR
SCHEMBL3525104 1.00 EGFR (0.63) EGFRERBB2ERBB4EPHA2KDR
SCHEMBL4732808 0.93 EGFR (0.60) EGFRERBB2ERBB4
SCHEMBL3523179 0.93 EGFR (0.60) EGFRERBB2ERBB4
SCHEMBL3525388 0.93 EGFR (0.60) EGFRERBB2ERBB4
SCHEMBL3523105 0.93 EGFR (0.60) EGFRERBB2ERBB4
SCHEMBL3519725 0.93 EGFR (0.60) EGFRERBB2ERBB4
SCHEMBL3525278 0.92 EGFR (0.57) EGFRERBB2ERBB4
SCHEMBL3525687 0.92 EGFR (0.57) EGFRERBB2ERBB4
SCHEMBL13499955 0.92 EGFR (0.52) EGFRERBB2EPHA2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622620-B1 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-02-20 EP disclosed
EP-1622620-A1 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AstraZeneca AB (SE) 2006-02-08 EP disclosed
WO-2004096226-A1 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2004-11-11 WO disclosed